Ligand activated transcriptional regulator proteins

Details Ligand activated transcriptional regulator proteins Ligand activated transcriptional regulator proteins

2003-04-23

2008-10-28

Spector, Lorraine (Department: 1647)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023500, C536S024100, C435S069100, C435S069700, C435S320100, C435S325000

Reexamination Certificate

active

07442784

ABSTRACT:
Fusion proteins for use as ligand-dependent transcriptional regulators are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to about 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells.

REFERENCES:
patent: 4394443 (1983-07-01), Weissman et al.
patent: 4446235 (1984-05-01), Seeburg
patent: 4990607 (1991-02-01), Katagiri et al.
patent: 5198346 (1993-03-01), Ladner et al.
patent: 5217867 (1993-06-01), Evans et al.
patent: 5364791 (1994-11-01), Vegeto et al.
patent: 5376530 (1994-12-01), De The et al.
patent: 5578483 (1996-11-01), Evans et al.
patent: 5789538 (1998-08-01), Rebar et al.
patent: 5874534 (1999-02-01), Vegeto et al.
patent: 5935934 (1999-08-01), Vegeto et al.
patent: 6140081 (2000-10-01), Barbas
patent: 6140466 (2000-10-01), Barbas, III et al.
patent: 6242568 (2001-06-01), Barbas, III et al.
patent: 6416998 (2002-07-01), O'Malley et al.
patent: 6534261 (2003-03-01), Cox, III et al.
patent: 6610512 (2003-08-01), Barbas
patent: 6723531 (2004-04-01), Evans et al.
patent: 6790941 (2004-09-01), Barbas, III et al.
patent: 2002/0081614 (2002-06-01), Case et al.
patent: 2002/0147327 (2002-10-01), O'Malley et al.
patent: 2002/0165356 (2002-11-01), Barbas, III et al.
patent: 2002/0168714 (2002-11-01), Barbas, III et al.
patent: 2002/0182698 (2002-12-01), O'Malley et al.
patent: 2003/0037355 (2003-02-01), Barbas, III et al.
patent: 2003/0059767 (2003-03-01), Barbas, III et al.
patent: 2003/0143559 (2003-07-01), Bracken et al.
patent: 2004/0224385 (2004-11-01), Barbas et al.
patent: 2005/0084885 (2005-04-01), Barbas, III et al.
patent: 2005/0148075 (2005-07-01), Barbas
patent: 0540065 (1993-05-01), None
patent: 9323431 (1993-11-01), None
patent: 9401548 (1994-01-01), None
patent: 9519431 (1995-07-01), None
patent: 9640911 (1996-12-01), None
patent: 9818925 (1998-05-01), None
patent: WO9818925 (1998-05-01), None
patent: 9854311 (1998-12-01), None
patent: 9945132 (1999-09-01), None
patent: 0023464 (2000-05-01), None
patent: 0130843 (2001-05-01), None
patent: 01/52620 (2001-07-01), None
patent: 02/06463 (2002-01-01), None
patent: WO 02/066640 (2002-08-01), None
patent: 02/097050 (2002-12-01), None
patent: WO 03/016496 (2003-02-01), None
patent: WO 03/066828 (2003-08-01), None
patent: WO 03/104414 (2003-12-01), None
Beerli et al 1998. PNAS. 95:14628-14633.
Robbins et al. 1998. Pharmacol. Ther. 80:35-47.
Clackson 2000. Gene Therapy. 7:120-125.
Kay et al., “Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics,” Nature Medicine 7(1):33-40, Jan. 2001.
Phillips, A. J., “The challenge of gene therapy and DNA delivery,” Journal of Pharmacy and Pharmacology 53(9):1169-1174, May 2001.
Thomas et al., “Progress and problems with the use of viral vectors for gene therapy,” Nature Reviews-Genetics 4:346-358, May 2003.
Eck, S.L. and J.M. Wilson, “Gene-based Therapy,” Chapter 5 inGoodman and Gilson's: The Pharmacological Basis of Therapeutics, 9thEdition, New York: McGraw-Hill, pp. 77-101 (1996).
Mikayama et al., “Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor,” Proc. Natl. Acad. Sci. USA 90: 10056-10060 (1993).
Voet, D. and J.G Voet,Biochemistry, New York: John Wiley & Sons, pp. 126-128 and 228-234 (1990).
Alwin et al., “Custom zinc-finger nucleases for use in human cells,” Mol. Ther. 12(4): 610-617 (2005).
Beerli, R.R.and C.F. Barbas III, “Engineering polydactyl zinc-finger transcription factors,” Nature Biotechnology 20(2): 135-41 (2002).
Blancafort et al., “Designing transcription factor architectures for drug discovery,” Mol. Pharmacol. 66(6): 1361-71 (2004).
Blancafort et al., “Genetic reprogramming of tumor cells by zinc finger transcription factors,” Proc. Natl. Acad. Sci. USA 102(33): 11716-21 (2005).
Blancafort et al., “Scanning the human genome with combinatorial transcription factor libraries,” Nature Biotechnol. 31(3):269-274 (2003).
Blau et al., “γ-globin gene expression in CID-dependent multi-potential cells established from beta-YAC transgenic mice,” J. Biol. Chem. Aug. 30, 2005.
Dreier et al., “Development of zinc finger domains for recognition of the 5′-ANN-3′ family of DNA sequences and their use in the construction of artificial transcription factors,” J. Biol. Chem. 276(31): 29466-78 (2001).
Dreier et al., “Development of zinc finger domains for recognition of the 5′-CNN-3′ family DNA sequences and their use in the construction of artificial transcription factors,” J. Biol. Chem. 280(42):35588-35597 (2005).
Graslund et al., “Exploring strategies for the design of artificial transcription factors: targeting sites proximal to known regulatory regions for the induction of γ-globin expression and the treatment of sickle cell disease,” J. Biol. Chem. 280(5): 3707-14 (2005).
Guan et al., “Heritable endogenous gene regulation in plants with designed polydactyl zinc finger transcription factors,” Proc. Natl. Acad. Sci. USA 99(20): 13296-301 (2002).
Lin et al., “Small-molecule switches for zinc finger transcription factors,” J. Am Chem. Soc. 125(3):612-3 (2003).
Lund et al., “Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation,” J. Mol. Biol. 340(3): 599-613 (2004).
Lund et al., “Zinc Finger Transcription Factors Designed for Bispecific Coregulation of ErB2 and ErbB3 Receptors: Insights into ErbB Receptor Biology,” Mol. Cell. Biol. 25(20): 9082-91 (2005).
Magnenat et al., “In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation,” J. Mol. Biol. 341(3): 635-49 (2004).
Ordiz et al., “Regulation of transgene expression in plants with polydactyl zinc finger transcription factors,” Proc. Natl. Acad. Sci. USA 99(20): 13290-5 (2002).
Segal et al., “Custom DNA-binding proteins come of age: polydactyl zinc-finger proteins,” Curr. Opin. Biotechnol. 12(6): 632-7 (2001).
Segal et al., “Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins,” Biochemistry 42(7): 2137-2148 (2003).
Segal et al., “Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor,” J. Biol. Chem. 279(15): 14509-19 (2004).
Segal et all., “Zinc fingers and a green thumb: manipulating gene expression in plants,” Curr. Opin. Plant Biol. 6(2): 163-8 (2003).
Stege et al., “Controlling gene expression in plants using synthetic zinc finger transcription factors,” Plant J. 32(6): 1077-86 (2002).
Tan et al. , “Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites,” J. Virol. 78(3): 1301-13 (2004).
Xu et al., “A versatile framework for the design of ligand-dependent, transgene-specific transcription factors,” Mol. Ther. 3(2): 262-73 (2001).
Agarwal et al. Stimulation of Transcript Elongation Requires both the Zinc Fingers and RNA Polymerase II Binding Domains of Human TFIIS,Biochemistry30:7842-51 (1991).
Altschul et al., Basic Local Alignment Search Tool,J. Mol. Biol. 215:403-410 (1990).
Aumais et al., elective Interaction of hsp90 with an Estrogen Receptor Ligand-binding Domain Containing a Point Mutation,J. Biol. Chem. 272(18):12229-35 (1997).
Ayer et

Affiliated with

Also associated with

Rating

Ligand activated transcriptional regulator proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ligand activated transcriptional regulator proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligand activated transcriptional regulator proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4005383